Navigation Links
NICE Gives the Final ‘NO’ to Roche’s Tarcva

NICE (National Institute of Health and Clinical Excellence) has given the ‘thumbs down’ signal to Roche's once-a-day lung cancer// pill Tarceva as its final decision on the matter. It says that the drug is of limited use and too expensive to be given on the NHS.

This decision will only flame the fires of controversy over access to expensive modern cancer treatments, as it follows bickering over whether Herceptin, another Roche product, should be given to women with early breast cancer.

Calling the action as ‘perverse’ and ‘flawed’ Roche is claiming a soon- to -be -followed appeal against NICE’s decision.

Charities have also appealed against the decision that will make needy patients opting for this drug to pay for them, out of their own pockets.

Mike Unger, chief executive of The Roy Castle Lung Cancer Foundation, says: "We are obviously severely disappointed and disillusioned with NICE’s decision not to approve Tarceva purely on economic grounds.

“It's the second blow that NICE has dealt to lung cancer patients in a month, following the announcement to decline Alimta - so there are now very few options left for lung cancer patients.”

NICE ‘s Chief Executive Andrew Dillon has come out against Roche saying that data has revealed that prescribing Tarceva is not an effective use of National Health Service resources when compared with using either Sanofi-Aventis' Taxotere or best supportive care.

Still Dillon has conceded that evidence on the drug is still emerging and has called for more research to test if certain sub- groups would benefit from the drug.

In defense, Roche says clinical trials have shown that Tarceva reduced symptoms of non-small-cell lung cancer, the most common type of the disease, and increased one-year survival rates by 41 percent.

Tarceva was licensed and launched in Britain in 2005 at a cost of 1,631 pounds for one month's treatment.

The medicine belongs to a new generation of "smart drugs", or targeted therapies, which attack only cancer cells and are tolerated much better than traditional chemotherapy.

Their high cost, however, stands in the way of its continued use, as governments and insurers around the world are already struggling to contain rising healthcare costs.

Source-Medinia
ANN
'"/>




Related medicine news :

1. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
2. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
3. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
4. US Doctors Association Gives away $110,000 To NGO’
5. Woman In Coma Gives Birth To Daughter
6. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
7. New Eye Surgery Gives Hope To Short-Sighted
8. Jharkhand Gives Health industry status
9. WHO Gives Its Approval For Bird Flu Test Kit
10. FDA Gives Its Approval For Inhaler
11. Congestion for Use of Clarinex-D 12 Hour cleared – FDA Gives the No
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... 09, 2016 , ... The Justin Veatch Fund announced Thursday that ... the film Whispering Spirits and its discussion guide for use by all ... tool in the war against teen drug abuse. NCADD is the oldest anti-addiction ...
(Date:12/9/2016)... ... 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated patient ... solution for Emergency Departments (ED) has been added to their portfolio. Housed in ... rooms, and with a simplified pallet of information available to the patient, the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Compensation Research Institute (WCRI) officially opened registration today for its 33rd Annual ... in Boston, MA . , The theme of the conference is “Persistent Challenges ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused on ... efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, Jr. ... honored to team up with Upstage Lung Cancer in order to make major strides ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... to its innovative Unified Instance Manager architecture, meeting the needs of multichannel ... version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides greater ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Texas , Dec. 9, 2016  RxWiki Inc., ... apps, and digital marketing strategies of thousands of pharmacies ... it won Austin Inno,s "50 on Fire" ... "We,re pleased to accept the award as ... Loughlin , Chief Executive Officer at RxWiki. "Our platform ...
(Date:12/9/2016)... Dec. 9, 2016  Forge Therapeutics, Inc. today ... Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance ... the treatment of bacterial infections including those caused ... as an attractive antibacterial target for more than ... suitable chemical starting points has hampered its progress. ...
(Date:12/8/2016)... NEW YORK , Dec. 8, 2016 ... ... such as reducing loss of blood during surgeries, lowering the ... surgeries, and decreasing risks of SSIs. The patient warming systems ... and intravascular warming systems.These benefits in turn reduce the stay ...
Breaking Medicine Technology: